Sample-to-answer workflows in genomics, diagnostics, and cell & gene therapy still run across fragmented systems — wet lab, sequencing, analysis, manufacturing or diagnosis, and clinic each operating with their own tools and manual hand-offs between them. AI and automation initiatives stall not because the models are weak, but because the underlying metadata was never unified in the first place.
The commercial question every platform, health system, and biopharma R&D group is quietly wrestling with: what does it take to become AI-ready, and what does that unlock commercially once it's built?
"You can have perfect data infrastructure but fail to bring along the medical writers or the clinical scientists… without adoption, there is no transformation."
McKinsey's life sciences leadership frames AI's promise as breaking down the organizational silos that have long separated research, clinical development, and patient care — but they're explicit that infrastructure is necessary, not sufficient, on its own.
Their own estimate: roughly 80% of life sciences workflows are structurally capable of AI/agent support, with organizations deploying at scale seeing 5–10% growth improvement and 3–5% margin improvement. The gap between that potential and realized value is exactly where commercial and technical readiness have to meet.
Whether it's an academic medical center's genomics program, a diagnostics lab, or a cell therapy manufacturer, the sample-to-answer path looks structurally the same — and so does where it breaks down.
A generalized pattern observed across genomics, diagnostics, and cell & gene therapy commercial engagements — not tied to any specific platform or client.
Different labs, different modalities, same four failure modes — each one a direct blocker to AI adoption, not just an operational nuisance.
No single view of where a sample or dataset is in its lifecycle — visibility ends at each system's own walls.
Spreadsheets and PDFs carry the hand-off between steps, introducing error and cost at every transition.
Without a structured audit trail, compliance (FDA, CLIA, CAP) and AI validation both run into the same wall: no trustworthy lineage.
Models need consistently structured, connected data. Fragmented systems can't feed one — no matter how good the model is.
The specific instruments and regulatory context shift by setting — the commercial thesis for closing the gap doesn't.
Multi-department programs running NGS, imaging, and clinical data through disconnected LIMS, EMR, and analysis tools, with no shared patient-to-sample metadata layer.
Commercial angle: a unified layer turns disconnected cohort data into a searchable research asset and shortens time-to-answer for clinicians and researchers alike.
Diagnostic developers coordinating sample receipt, third-party wet lab processing, sequencing, and bioinformatics across multiple vendors and cloud handoffs.
Commercial angle: automated data ingest and provenance tracking across vendor boundaries de-risks scale-up and shortens report turnaround.
Patient-specific manufacturing processes requiring chain-of-identity and chain-of-custody documentation from procurement through infusion — traditionally paper-based.
Commercial angle: digitized batch records reduce manufacturing cost per patient and strengthen the regulatory story for commercial launch.
Discovery data spread across instrument software, ELNs, and cloud storage with no consistent structure — the exact condition that stalls AI pilots before production.
Commercial angle: AI-readiness becomes a partnering and fundraising asset, not just an IT project — it's increasingly what diligence looks for.
A commercial framework for diagnosing where your data infrastructure stands today, and what it takes to make AI adoption viable — built on years of platform commercialization experience across genomics, diagnostics, and cell & gene therapy.